Take Our PhysQuiz on ACR Convergence 2020!
Test your knowledge on results on PsA released at ACR Convergence 2020 – take our quiz and...
ACR Convergence 2020
ACR Convergence 2020 Highlights – eBook
Convergence Psoriasis Report v1.indd Featuring Phase III PALACE 4: Apremilast Sustains PsA...
ACR 2020: COVID-19 Impact On DMARD Changes
Researchers conducted a study to assess the medical and clinical changes patients with rheumatoid...
ACR 2020: Delay in Transition from Psoriasis to Psoriatic Arthritis
Psoriatic arthritis (PsA) is a heterogeneous disease which may precede, occur concurrently, or...
ACR 2020: Psoriatic Arthritis And Impact of Unacceptable Symptom State
Despite numerous effective therapies for patients with psoriatic arthritis (PsA), many do not...
ACR 2020: Guselkumab in Psoriasis Patients with and Without Psoriatic Arthritis
Guselkumab (GUS), a fully human monoclonal antibody, selectively binds and blocks IL-23. VOYAGE 1...
ACR 2020: Ixekizumab in Patients with Psoriatic Arthritis
Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets interleukin-17A....
Autotaxin inhibition: a fascinating novel treatment approach for cutaneous lupus patients
The autotaxin inhibitor ziritaxestat proved to be efficacious and tolerable in the first randomised, double-blind, placebo-controlled phase 2 trial ever conducted in patients with diffuse cutaneous systemic sclerosis....
New treatment possibility for giant cell arteritis on the horizon
The anti-GM-CSF receptor alpha monoclonal antibody mavrilimumab entailed a lower risk of flare and greater sustained remission compared with placebo in patients with giant cell arteritis. A phase 2, randomised,...
Risk of knee and hip replacement linked to use of vitamin K antagonist
In patients with osteoarthritis, a new study found that the vitamin K antagonist warfarin medication was associated with a significantly increased risk of joint replacement compared with treatment with direct oral...
Hydroxychloroquine is not associated with arrhythmias in patients with rheumatic disease
An analysis of 681 patients with rheumatoid arthritis and systemic lupus erythematosus revealed that hydroxychloroquine use is not associated with QTc length prolongation, even when given in combination with other QTc-prolonging...
Inflammatory diseases possibly linked to fracture risk
An Italian cohort study in women observed an increased fracture risk in rheumatoid arthritis and other inflammatory diseases, which was independent of treatment with corticosteroids. “We all know that glucocorticoid-induced...
